奥英妥珠单抗在复发/难治性急性淋巴细胞白血病治疗中的作用。
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
作者信息
George Binsah, Kantarjian Hagop, Jabbour Elias, Jain Nitin
机构信息
Department of Leukemia, MD Anderson Cancer Centre, Houston, TX 77030, USA.
出版信息
Immunotherapy. 2016 Feb;8(2):135-43. doi: 10.2217/imt.15.108. Epub 2016 Jan 18.
Abstract
Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.
摘要
奥英妥珠单抗是一种与毒性天然加利车霉素结合的人源化抗CD22单克隆抗体，目前正用于复发性/难治性急性淋巴细胞白血病的治疗研究。CD22通常在90%-100%的恶性成熟B淋巴细胞谱系中表达。坎塔尔吉安等人进行的第一项关于奥英妥珠单抗的II期研究，为接受过大量预处理的急性淋巴细胞白血病患者提供了进行异基因干细胞移植的机会。除了静脉闭塞性疾病外，奥英妥珠单抗耐受性良好。总体而言，奥英妥珠单抗对患者来说可能是一种令人鼓舞且有前景的治疗方法。
相似文献
1
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.奥英妥珠单抗在复发/难治性急性淋巴细胞白血病治疗中的作用。
Immunotherapy. 2016 Feb;8(2):135-43. doi: 10.2217/imt.15.108. Epub 2016 Jan 18.
2
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.依妥珠单抗奥滨尤妥珠单抗治疗难治性/复发急性淋巴细胞白血病的疗效。
Cancer. 2013 Aug 1;119(15):2728-36. doi: 10.1002/cncr.28136. Epub 2013 Apr 30.
3
[Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].[剂量调整型奥英妥珠单抗两剂量方案治疗复发/难治性B细胞急性淋巴细胞白血病的疗效]
Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):911-916. doi: 10.3760/cma.j.issn.0253-2727.2023.11.005.
4
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.依妥珠单抗奥滨尤妥珠单抗与低强度化疗联合用于费城染色体阴性的老年急性淋巴细胞白血病患者：一项单臂、2 期研究。
Lancet Oncol. 2018 Feb;19(2):240-248. doi: 10.1016/S1470-2045(18)30011-1. Epub 2018 Jan 16.
5
Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.奥英妥珠单抗用于治疗急性淋巴细胞白血病患者。
Drugs Today (Barc). 2017 Dec;53(12):653-665. doi: 10.1358/dot.2017.53.12.2737934.
6
Inotuzumab Ozogamicin: First Pediatric Approval.依妥珠单抗奥佐米星：首款获儿科批准的药物。
Paediatr Drugs. 2024 Jul;26(4):459-467. doi: 10.1007/s40272-024-00634-w. Epub 2024 May 23.
7
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.奥英妥珠单抗：一种用于成人复发或难治性B细胞前体急性淋巴细胞白血病的CD22单克隆抗体-药物偶联物。
Drug Des Devel Ther. 2018 Jul 24;12:2293-2300. doi: 10.2147/DDDT.S150317. eCollection 2018.
8
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
9
Inotuzumab Ozogamicin: First Global Approval.依妥珠单抗奥滨尤妥珠单抗：全球首次获批
Drugs. 2017 Sep;77(14):1603-1610. doi: 10.1007/s40265-017-0802-5.
10
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.挽救性化疗免疫治疗联合 Inotuzumab Ozogamicin 联合 Mini-Hyper-CVD 治疗费城染色体阴性复发或难治性急性淋巴细胞白血病患者：一项 2 期临床试验。
JAMA Oncol. 2018 Feb 1;4(2):230-234. doi: 10.1001/jamaoncol.2017.2380.
引用本文的文献
1
Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery.用于抗原和肿瘤微环境依赖性细胞内货物递送的肿瘤特异性胞质穿透抗体。
Mol Ther Oncol. 2025 Jan 2;33(1):200931. doi: 10.1016/j.omton.2024.200931. eCollection 2025 Mar 20.
2
Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents.将微生物代谢产物中的生物活性小分子重新定义为革命性的抗癌药物。
Cancer Gene Ther. 2024 Feb;31(2):187-206. doi: 10.1038/s41417-023-00715-x. Epub 2024 Jan 10.
3
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.博纳吐单抗与奥英妥珠单抗序贯治疗复发/难治性急性淋巴细胞白血病：一项真实世界全校园研究
Cancers (Basel). 2023 Sep 19;15(18):4623. doi: 10.3390/cancers15184623.
4
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.托西珠单抗治疗嵌合抗原受体 T 细胞引起的细胞因子释放综合征。
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. doi: 10.1080/1744666X.2019.1629904. Epub 2019 Jun 20.
5
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.奥英妥珠单抗治疗复发或难治性B细胞急性淋巴细胞白血病
J Adv Pract Oncol. 2018 Sep-Oct;9(6):670-676. Epub 2018 Sep 1.
6
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.因诺妥珠单抗奥佐米星用于急性淋巴细胞白血病和非霍奇金淋巴瘤的临床开发。
Biomark Res. 2019 Apr 11;7:9. doi: 10.1186/s40364-019-0160-4. eCollection 2019.
7
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.Chk1抑制恢复表达突变型p53的CD22阳性细胞中奥英妥珠单抗的细胞毒性。
Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.
8
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.急性淋巴细胞白血病的双特异性抗体、抗体药物偶联物和含抗体方案的临床试验更新。
J Hematol Oncol. 2019 Feb 8;12(1):15. doi: 10.1186/s13045-019-0703-z.
9
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.奥英妥珠单抗：一种用于成人复发或难治性B细胞前体急性淋巴细胞白血病的CD22单克隆抗体-药物偶联物。
Drug Des Devel Ther. 2018 Jul 24;12:2293-2300. doi: 10.2147/DDDT.S150317. eCollection 2018.
本文引用的文献
1
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.奥英妥珠单抗治疗复发或难治性CD22阳性成人急性淋巴细胞白血病：一项1/2期研究。
Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925.
2
Genomics in acute lymphoblastic leukaemia: insights and treatment implications.急性淋巴细胞白血病的基因组学：见解与治疗意义。
Nat Rev Clin Oncol. 2015 Jun;12(6):344-57. doi: 10.1038/nrclinonc.2015.38. Epub 2015 Mar 17.
3
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.奥英妥珠单抗治疗B细胞急性淋巴细胞白血病和非霍奇金淋巴瘤。
Expert Opin Biol Ther. 2015 Apr;15(4):601-11. doi: 10.1517/14712598.2015.1024652.
4
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.使用CD22单克隆抗体奥英妥珠单抗治疗难治性和复发性急性淋巴细胞白血病患者的预后因素
Am J Hematol. 2015 Mar;90(3):193-6. doi: 10.1002/ajh.23901. Epub 2015 Jan 16.
5
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.奥英妥珠单抗在血液系统恶性肿瘤中的临床前及临床开发
Mol Immunol. 2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7.
6
Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.B细胞系急性淋巴细胞白血病的抗体疗法
Eur J Haematol. 2015 Feb;94(2):99-108. doi: 10.1111/ejh.12408. Epub 2014 Aug 18.
7
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.奥英妥珠单抗治疗急性淋巴细胞白血病
Front Biosci (Elite Ed). 2014 Jan 1;6(1):40-5. doi: 10.2741/e688.
8
Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.儿童复发 B 细胞急性淋巴细胞白血病患者应用 CMC-544（奥加米妥珠单抗）的初步经验。
Pediatr Blood Cancer. 2014 Feb;61(2):369-72. doi: 10.1002/pbc.24721. Epub 2013 Sep 2.
9
Novel targeted therapies in acute lymphoblastic leukemia.急性淋巴细胞白血病的新型靶向治疗
Leuk Lymphoma. 2014 Apr;55(4):737-48. doi: 10.3109/10428194.2013.823493. Epub 2013 Aug 28.
10
Targeting CD22 in B-cell malignancies: current status and clinical outlook.靶向 B 细胞恶性肿瘤的 CD22：现状与临床展望。
BioDrugs. 2013 Aug;27(4):293-304. doi: 10.1007/s40259-013-0016-7.
Zotero 插件